lily Chang

Ms. Chang boasts nearly 15 years of experience in generic drugs and 505(b)(2) new drug development. Her core products are indicated for psychiatric diseases (depression, Alzheimer’s disease), hypoglycemia and hypertension.

She has completed validation batches for multiple products and passed official BE trials. Over ten projects have been approved for IND in China with expected PK outcomes obtained. A number of projects have been submitted for and granted approval of Chinese and US ANDA applications. She also has rich experience in external cooperation of pharmaceutical products.

She graduated from Xuzhou Medical University, majoring in Pharmaceutics.